—Cooperative Research and Development Agreement (CRADA) will utilize Apertura's TfR1 CapX™ Capsid— —Ara Parseghian Medical Research Fund, a non-profit organization dedicated to finding a treatment or cure for Niemann-Pick Type C, will contribute financial support to the research— July 9, 2026 -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced that it has entered into a Cooperative Research and Development Ag

Ipsen announced Thursday that Dysport (abobotulinumtoxinA) hit the mark in a pair of late-stage trials, marking the first time a botulinum toxin has shown efficacy across both chronic and episodic forms of migraine. The Phase III BEOND programme enrolled 1510 adults across two studies — C-BEOND and E-BEOND — pitting Dysport against placebo, with the trials' primary efficacy endpoint being change in monthly migraine days at week 24. Top-line results showed Dysport met its primary goals in both

New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia’s intellectual property portfolio supporting its FAK inhibitor program If granted, patent protection for the new molecules and their use would extend to 2046 New compounds broaden pipeline optionality and may support future development and partnering opportunities July 09, 2026 -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to

ART5803 is a precision therapeutic candidate designed to directly inhibit the pathogenic effects of anti-NMDA receptor autoantibodies Fast Track designation enables a more expedited regulatory review of ART5803, which has also received U.S. FDA Orphan Drug and Rare Pediatric Disease designations, as well as Orphan Drug designation from South Korea’s MFDS. Arialys Therapeutics, a clinical-stage biotechnology company pioneering precision medicines for autoimmune neuropsychiatric diseases, today

Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. The financing will scale manufacturing, accelerate commercial deployment

In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered symptom burden in patients with chronic obstructive pulmonary disorder. AstraZeneca has gone on another excursion to Asia, this time enlisting Sino Biopharmaceutical for a global licensing deal to address a chronic respiratory disorder. The pharma is paying $200 million upfront and offering up to $1.9

Additional capital brings total raised to $150 million in a Series C financing Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinic

July 8, 2026 -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot. The pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placeb

July 8, 2026 -- Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist and Modulator (SEGRAM), is an orally available investigational compound being developed to provide an alternative to glucocorticoid-based treatments such as prednisone, t

– Comprehensive updates to be presented at Barth Syndrome Foundation conference – July 8, 2026 -- Mighty Therapeutics (the "Company" or "Mighty"), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced that the first patient has been dosed in 4TAZPower, its global Phase 4 study to confirm the efficacy, safety, and pharmacokinetics of once-daily elamipretide in individuals at le